Symbols

AKTS

Aktis Oncology·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Buy"

EPS Beats Expectation

Bearish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AKTS

Aktis Oncology, Inc.

A clinical-stage oncology company

Industry

Biological Technology

Established Date

Listing Date

01/09/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.aktisoncology.com

Security Type

Common stock

Office address

17 Drydock Avenue Suite 17-401 Boston Massachusetts 02210

Business

Introduction

Aktis Oncology, Inc. was incorporated under the laws of the State of Delaware in August 2020. The company is a clinical-stage oncology company that leverages its proprietary small protein platform to develop targeted radiopharmaceuticals. Its lead drug candidate [225Ac] Ac-AKY-1189 targets Nectin-4 and is currently in Phase 1 b clinical development for urothelial carcinoma and other solid tumors expressing Nectin-4.

Company Financials

EPS

Revenue & Expenses

AKTS has released its 2025 Q4 earnings report, with revenue of 1.87M, reflecting a YoY change of 100.43%, and net profit of -15.14M, showing a YoY change of -25.56%. The Sankey diagram below clearly presents AKTS's revenue sources and cost distribution.